glp 1 agonis New GLP-1 Guidelines for Type 2 Diabetes in 2025 The Influence of GLP-1 Agonists

Weekly GLP-1 and GIP medications for weight management and metabolic health

Elon Musk wants to cut funding for scientific research, but the weight loss drugs he promoted also came from government funded basic science.

The booming GLP-1 market, projected to reach $167bn by 2031, presents compelling opportunities for private equity players to carve out their niche and capture substantial value, despite industry giants Novo Nordisk and Eli Lilly dominating the lions share of the market. Download PDF

Surgeon's guide to the evidence, symptoms and when to seek assessment in Hampshire.

Drugmaker Lilly said its experimental pill, orforglipron, produced better blood sugar and weight loss for diabetes patients results in a new head-to-head clinical trial.

Statement development was guided by a systematic literature review and 12 global experts